Montrouge, France, November 9, 2022
DBv Technologies to stand out New clinic Data in the ACAAI 2022
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new clinical data on the use of Viaskin™ Peanut (DBV712) 250 μg in young children peanut allergic11 to 3 years will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, November 10-14, 2022 in Louisville, KY. Two abstracts have been accepted, including an oral presentation and a poster presentation. These presentations will be available on DBV’s website, www.dbv-technologies.com, after the meeting for those unable to attend. DBV will also host a booth in the ACAAI exhibit hall from Friday, November 11 to Sunday, November 13.
This year’s meeting will also feature a “Product Theatre” on the evolution of the prevention and treatment of peanut allergy in young children. Professors Gideon Lack, MD, and J. Andrew Bird, MD, will participate in a lively discussion on how evidence from studies of prevention and treatment of peanut allergy in young children can impact current and future clinical practice . The Product Theater is scheduled for Saturday, November 12th, from 9:35 to 10:00 AM EST in the Exhibit Hall, Upper Concourse.
DBV is the sole sponsor, through an independent educational grant, of the International Food Allergy Symposium, a full-day symposium initiated by the ACAAI. Leading experts from around the world will present on various topics related to food allergy, including epidemiology, diagnosis, prevention and treatment. The symposium is scheduled for Thursday, November 10, from 8:00 AM to 6:00 PM EST. The company also sponsors the 31st annual FIT Bowl, a game show-style competition that tests the knowledge of participating teams from training programs across the country. The competition will be held on Saturday, November 12th from 5:30pm to 7:30pm EST in Commonwealth Ballrooms 1 and 2.
“There is a significant unmet need that persists among young children with peanut allergy. Additional data being presented at this year’s ACAAI meeting highlight Viaskin Peanut’s potential as a treatment option for this young and vulnerable patient population if approved,” said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies. “Wecontinue workingtoward seeking approvalto carry this noveltreatment optionin the marketas quickly as possible”.
Viaskin Peanut is the company’s lead product candidate designed to reduce the risk of allergic reactions due to accidental exposure to peanuts. Viaskin Peanut, an investigational, non-invasive, once-daily epidermal patch, aims to deliver microgram amounts of peanut antigen to re-educate the immune system. The safety and efficacy of Viaskin Peanut have not yet been established by the US Food and Drug Administration or the European Medicines Agency. Viaskin is DBV’s patented approach to epicutaneous immunotherapy (EPIT™), a method of delivering biologically active compounds to the immune system through the skin.
“Results of the EPITOPE Study: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Epicutaneous Immunotherapy in Peanut-Allergic Young Children” will be presented by Matthew Greenhawt, MD, M.Sc., MBA, FACAAI, Children’s Hospital Colorado, Aurora, CO.
- Presentation ID: D019
- Session title: Distinguished Industry Oral Abstracts – Session B
- Presentation date: Saturday, November 12
- Show Time: 4:30pm to 5:30pm EST
- Place of presentation: Room M104 – M107
Presentation of the poster
“Reduction in reaction severity after 12 months of epicutaneous peanut patch immunotherapy in young children“ will be presented by Terri Brown-Whitehorn, MD, Children’s Hospital of Philadelphia, Philadelphia, PA.
- Presentation ID: P183
- Session title: ePoster – Meet the author
- Presentation date: Friday, November 11
- File time: 3:00 PM EST
- Place of presentation: Exhibition hall (Superior Apartment), Monitor 16
About DBV Technologies
DBV Technologies is developing Viaskin™, a proprietary research technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergy programs include ongoing Viaskin Peanut clinical trials. DBV Technologies has global headquarters in Montrouge, France and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are listed on the B segment of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (representing one half of an ordinary share) are listed on the Nasdaq Global Select Market ( Ticker: DBVT).
This press release may contain forward-looking statements and estimates, including statements about the therapeutic potential of Viaskin™ Peanut as a treatment for peanut-allergic children and the potential benefits of EPIT™. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties and may be affected by market conditions, as well as other risks and uncertainties set forth in DBV Technologies’ regulatory filings with the Autorité des Marchés Financiers (” AMF” ), DBV Technologies’ filings and reports with the US Securities and Exchange Commission (“SEC”), and future filings and reports made with the AMF and the SEC. Existing and potential investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this press release.
Contact with the media
Viaskin and EPIT are trademarks of DBV Technologies.